Literature DB >> 17406078

HIV testing: rationale for changing recommendations.

Robert S Janssen1.   

Abstract

HIV testing is an important and effective strategy for preventing HIV infection. Infected individuals who know their HIV serostatus are less likely to engage in high-risk sexual behavior, and it is estimated that knowledge of HIV serostatus in unaware persons could reduce new infections by more than 30%. The availability of rapid testing for HIV expands testing opportunities. Expanded routine, voluntary, and opt-out screening in health care settings is needed to reduce the number of persons who are unaware of their HIV-infected status, get newly diagnosed patients into care, and reduce transmission of HIV infection. This article summarizes a presentation on revisions to Centers for Disease Control and Prevention HIV screening recommendations made by Robert S. Janssen, MD, at the 9th Annual Ryan White CARE Act Clinical Update in Washington, DC, in August 2006. The original presentation is available as a Webcast at www.iasusa.org.

Entities:  

Mesh:

Year:  2007        PMID: 17406078

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  3 in total

1.  Supporting the integration of HIV testing into primary care settings.

Authors:  Janet J Myers; Lucy Bradley-Springer; Mi-Suk Kang Dufour; Kimberly A Koester; Stephanie Beane; Nancy Warren; Jeffrey Beal; Linda Rose Frank
Journal:  Am J Public Health       Date:  2012-04-19       Impact factor: 9.308

2.  High-volume rapid HIV testing in an urban emergency department.

Authors:  Yvette Calderon; Jason Leider; Susan Hailpern; Robert Chin; Reena Ghosh; Jade Fettig; Paul Gennis; Polly Bijur; Laurie Bauman
Journal:  AIDS Patient Care STDS       Date:  2009-09       Impact factor: 5.078

3.  Nonmedical prescription drug users in private vs. public substance abuse treatment: a cross sectional comparison of demographic and HIV risk behavior profiles.

Authors:  Catherine L O'Grady; Hilary L Surratt; Steven P Kurtz; Maria A Levi-Minzi
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.